Staccato® Granisetron Multiple Dose PK

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

To examine the tolerability and safety of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers To characterize the pharmacokinetics of AZ-010 following 7 days of dosing (up to 3 mg) in healthy volunteers

Key facts

Study ID

NCT04327765

Run by

Alexza Pharmaceuticals, Inc.

People needed

30

Starts

2020-03-10

Expected to finish

2020-08-15

Last updated by the study team

2020-10-30

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit and prior to the first dose of study drug.
• Body weight ≥ 50 kg and BMI within the range of 18 to 32 kg/m2, inclusive, at screening.
• Negative urine tests for selected drugs of abuse and alcohol breath test at screening and Day 1.

You may not qualify if…

• Any significant medical condition

Where it is running

• Celerion — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.